244 related articles for article (PubMed ID: 22490510)
1. Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.
Raamanathan A; Simmons GW; Christodoulides N; Floriano PN; Furmaga WB; Redding SW; Lu KH; Bast RC; McDevitt JT
Cancer Prev Res (Phila); 2012 May; 5(5):706-16. PubMed ID: 22490510
[TBL] [Abstract][Full Text] [Related]
2. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT
Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014
[TBL] [Abstract][Full Text] [Related]
3. Bead-based ELISA for validation of ovarian cancer early detection markers.
Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
[TBL] [Abstract][Full Text] [Related]
4. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
5. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
[TBL] [Abstract][Full Text] [Related]
6. Programmable Bio-nanochip Platform: A Point-of-Care Biosensor System with the Capacity To Learn.
McRae MP; Simmons G; Wong J; McDevitt JT
Acc Chem Res; 2016 Jul; 49(7):1359-68. PubMed ID: 27380817
[TBL] [Abstract][Full Text] [Related]
7. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.
Wang S; Zhao X; Khimji I; Akbas R; Qiu W; Edwards D; Cramer DW; Ye B; Demirci U
Lab Chip; 2011 Oct; 11(20):3411-8. PubMed ID: 21881677
[TBL] [Abstract][Full Text] [Related]
8. Lab-on-a-Disc for Point-of-Care Infection Diagnostics.
Sunkara V; Kumar S; Sabaté Del Río J; Kim I; Cho YK
Acc Chem Res; 2021 Oct; 54(19):3643-3655. PubMed ID: 34516092
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
[TBL] [Abstract][Full Text] [Related]
10. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
11. Programmable bio-nano-chip system: a flexible point-of-care platform for bioscience and clinical measurements.
McRae MP; Simmons GW; Wong J; Shadfan B; Gopalkrishnan S; Christodoulides N; McDevitt JT
Lab Chip; 2015 Oct; 15(20):4020-31. PubMed ID: 26308851
[TBL] [Abstract][Full Text] [Related]
12. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels.
Jokerst JV; Raamanathan A; Christodoulides N; Floriano PN; Pollard AA; Simmons GW; Wong J; Gage C; Furmaga WB; Redding SW; McDevitt JT
Biosens Bioelectron; 2009 Aug; 24(12):3622-9. PubMed ID: 19576756
[TBL] [Abstract][Full Text] [Related]
13. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.
Drescher CW; Shah C; Thorpe J; O'Briant K; Anderson GL; Berg CD; Urban N; McIntosh MW
J Clin Oncol; 2013 Jan; 31(3):387-92. PubMed ID: 23248253
[TBL] [Abstract][Full Text] [Related]
15. Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Jafari M; Hasanzadeh M; Solhi E; Hassanpour S; Shadjou N; Mokhtarzadeh A; Jouyban A; Mahboob S
Int J Biol Macromol; 2019 Apr; 126():1255-1265. PubMed ID: 30615961
[TBL] [Abstract][Full Text] [Related]
16. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
17. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
Holdenrieder S; Molina R; Gion M; Gressner A; Troalen F; Auge JM; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):588-99. PubMed ID: 18598201
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
20. Ultrasensitive immunoassay of carcinoma antigen 125 in untreated human plasma samples using gold nanoparticles with flower like morphology: A new platform in early stage diagnosis of ovarian cancer and efficient management.
Hasanzadeh M; Sahmani R; Solhi E; Mokhtarzadeh A; Shadjou N; Mahboob S
Int J Biol Macromol; 2018 Nov; 119():913-925. PubMed ID: 30081127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
